Oryzon Genomics, S.A. announced that it will present new clinical data and present company updates at several renowned international conferences in November and December. The company will present a 36 month clinical update of the ongoing iadademstat?s ALICE Phase II trial in acute myeloid leukemia at the 63th American Society of Hematology 2021 Congress, which will be held December 11-14 in Atlanta, GA. This clinical update will be presented as a poster entitled ?Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients? on December 13th. ALICE is a single arm, open-label Phase IIa clinical trial evaluating the safety, tolerability, dose finding and efficacy of iadademstat in combination with azacitidine in older patients with AML in first line therapy. In accordance with the embargo terms and conditions for presentation at the ASH Congress, data will be released on the same day as the communication, December 13, 2021. Iadademstat is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers. A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer, neuroendocrine tumors, medulloblastoma and others. Iadademstat has been tested in four clinical trials in more than 100 patients. In the combination studies, ALICE, a Phase IIa trial in combination with azacitidine in elderly or unfit AML patients, and CLEPSIDRA (finalized), a Phase IIa trial in combination with platinum/etoposide in second line ED-SCLC patients, preliminary efficacy results have been reported. Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer?s disease, to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis. Oryzon has performed two Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders and in aggressive/agitated patients with moderate or severe AD, with positive clinical results reported in both. Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL trial in patients with Mild to Moderate AD, where a significant reduction of the inflammatory biomarker YKL40 has been observed after 6 and 12 months of treatment, and the pilot, small scale SATEEN trial in Relapse-Remitting and Secondary Progressive MS, where antiinflammatory activity has also been observed. Vafidemstat has also been tested in a Phase II in severe Covid-19 patients assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection, where it showed significant anti-inflammatory effects in severe Covid-19 patients. Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder and in schizophrenia patients. The company is also deploying a CNS precision medicine approach with vafidemstat in genetically-defined patient subpopulations of certain CNS disorders.